共 50 条
- [31] Characterization of AZD5363, an orally bioavailable, potent ATP-competitive inhibitor of AKT kinases with pharmacodynamic and antitumor activity in preclinical modelsCANCER RESEARCH, 2011, 71Davies, Barry R.Luke, RichardDudley, PhillippaGreenwood, HannahCrafter, ClaireCosulich, SabinaPage, KenYates, JamesLane, ClareYu, DerekZhang, JingchuanPass, Martin
- [32] Discovery and preclinical characterization of ISM9342A, a novel, potent, and orally bioavailable WRN inhibitor that suppresses MSI-H tumor growthCANCER RESEARCH, 2024, 84 (06)Zhao, PeiZhu, WeiDing, XiaoyuWan, JianfeiChen, XiaojingZhang, ManDing, XiaoBavadekar, SupriyaRao, SujataRen, FengZhavoronkov, Alex
- [33] Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical SpeciesJOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 7226 - 7242Yang, WuWang, YufengLai, AmyClark, Charles G.Corte, James R.Fang, TiananGilligan, Paul J.Jeon, YoonPabbisetty, Kumar B.Rampulla, Richard A.Mathur, ArvindKaspady, MahammedNeithnadka, Premsai RaiArumugam, ArunachalamRaju, SivashankaranRossi, Karen A.Myers, Joseph E., Jr.Sheriff, StevenLou, ZhenZheng, Joanna J.Chacko, Silvi A.Bozarth, Jeffrey M.Wu, YimingCrain, Earl J.Wong, Pancras C.Seiffert, Dietmar A.Luettgen, Joseph M.Lam, Patrick Y. S.Wexler, Ruth R.Ewing, William R.
- [34] PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE HEPATITIS B VIRAL ENTRY INHIBITOR A2342HEPATOLOGY, 2021, 74 : 512A - 513ALindstrom, ErikGillberg, Per-GoranUzelac, IvanaStarke, IngemarBonn, BrittaStrangberg, EllenMattsson, JanAkerblad, PeterPal, RunaGaur, AshwaniKangarajan, RameshSingh, ShivendraKulkarni, SantoshTruong, JenniferRao, AnuradhaDawson, Paul A.
- [35] Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitorINVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 810 - 818Haney, Staci L.Chhonker, Yashpal S.Varney, Michelle L.Talmon, GeoffreyMurry, Daryl J.Holstein, Sarah A.
- [36] Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitorInvestigational New Drugs, 2018, 36 : 810 - 818Staci L. HaneyYashpal S. ChhonkerMichelle L. VarneyGeoffrey TalmonDaryl J. MurrySarah A. Holstein
- [37] Preclinical Investigation of a Potent Geranylgeranyl Diphosphate Synthase InhibitorBLOOD, 2017, 130Haney, Staci L.Chhonker, Yashpal S.Varney, Michelle L.Talmon, Geoffrey A.Murry, Daryl J.Holstein, Sarah A.
- [38] Preclinical evaluation of WX-0593, a potent orally active ALK inhibitorCANCER RESEARCH, 2018, 78 (13)Liu XileDing, Charles Z.Mao, WeifengQin, YuxinZheng, ShansongYang, YingyingZheng, QingmeiZhang, LongZhao, Shuyong
- [39] UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual InhibitorJOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 7031 - 7041Zhang, WeiheDeRyckere, DeborahHunter, DebraLiu, JingStashko, Michael A.Minson, Katherine A.Cummings, Christopher T.Lee, MinjungGlaros, Trevor G.Newton, Dianne L.Sather, SusanZhang, DehuiKireev, DmitriJanzen, William P.Earp, H. SheltonGraham, Douglas K.Frye, Stephen V.Wang, Xiaodong
- [40] Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase InhibitorJOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) : 6368 - 6377Cee, Victor J.Schenkel, Laurie B.Hodous, Brian L.Deak, Holly L.Nguyen, Hanh N.Olivieri, Philip R.Romero, KarinaBak, AnnetteBe, XuhaiBellon, SteveBush, Tammy L.Cheng, Alan C.Chung, GraceCoats, SteveEden, Patrick M.Hanestad, KellyGallant, Paul L.Gu, YanHuang, XinKendall, Richard L.Lin, Min-Hwa JasmineMorrison, Michael J.Patel, Vinod F.Radinsky, RobertRose, Paul E.Ross, SandraSun, Ji-RongTang, JinZhao, HuilinPayton, MarcGeuns-Meyer, Stephanie D.